List of Excipients in Branded Drug BRIDION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	BRIDION	sugammadex	0006-5423	HYDROCHLORIC ACID
Merck Sharp & Dohme LLC	BRIDION	sugammadex	0006-5423	SODIUM HYDROXIDE
Merck Sharp & Dohme LLC	BRIDION	sugammadex	0006-5423	WATER
Medical Purchasing Solutions LLC	BRIDION	sugammadex	71872-7187	HYDROCHLORIC ACID
Medical Purchasing Solutions LLC	BRIDION	sugammadex	71872-7187	SODIUM HYDROXIDE

Bridion Excipient Strategy and Commercial Opportunities for Sugammadex

Last updated: October 12, 2026

Bridion is a sterile, preservative-free sugammadex sodium injection with an unusually simple excipient profile. The U.S. formulation contains hydrochloric acid and sodium hydroxide for pH adjustment, with water for injection as the vehicle. The commercial opportunity is therefore less likely to come from conventional excipient substitution and more likely to come from injectable-grade supply, container-closure systems, ready-to-administer presentations, stability enhancement, and differentiated hospital packaging.

What excipients are used in Bridion?

Bridion contains sugammadex sodium at 100 mg/mL. Its listed inactive ingredients are hydrochloric acid and sodium hydroxide, used to adjust pH, in water for injection. The product is supplied as a single-dose, preservative-free solution in 2-mL and 5-mL vials containing 200 mg and 500 mg of sugammadex, respectively (Merck Sharp & Dohme LLC, 2023).

Attribute	Bridion characteristic
Active ingredient	Sugammadex sodium
Strength	100 mg/mL
Dosage form	Sterile intravenous injection
Vial sizes	200 mg/2 mL and 500 mg/5 mL
Preservative	None listed
Primary excipient	Water for injection
pH agents	Hydrochloric acid and sodium hydroxide
Administration	Intravenous use
Storage	Controlled room temperature; product-specific labeling applies
Commercial manufacturer	Merck Sharp & Dohme LLC

Sugammadex is a modified gamma-cyclodextrin. The cyclodextrin structure is the pharmacologically active molecule that encapsulates steroidal neuromuscular blocking agents, including rocuronium and vecuronium. This distinguishes Bridion from products in which cyclodextrins are only solubilizing or stabilizing excipients.

Why is Bridion’s excipient profile commercially important?

The formulation has limited conventional excipient content, which reduces substitution opportunities but raises the importance of quality, supply continuity, and presentation engineering.

Three commercial characteristics matter:

1. The product is a high-dose injectable with a large active load.
2. It is administered in the operating room, where preparation time and dosing errors affect purchasing decisions.
3. It is preservative-free and supplied in single-dose containers, limiting the value of conventional multidose preservation strategies.

Because hydrochloric acid, sodium hydroxide, and water for injection are established parenteral materials, a competing product would gain limited differentiation from simply replacing one pH-adjusting agent with another. A stronger strategy would combine formulation work with a new container, administration system, or stability claim.

What formulation opportunities exist for sugammadex products?

Ready-to-administer syringes

A prefilled syringe could reduce vial handling and preparation time in operating rooms. The principal development issues would include:

• Compatibility between sugammadex and syringe components.
• Silicone oil and tungsten residue control.
• Extractables and leachables.
• Needle or connector compatibility.
• Dose accuracy at 2 mL and 5 mL fill volumes.
• Protection from accidental product loss during emergency use.

A ready-to-administer product could command a premium if it reduces pharmacy compounding or bedside preparation. Its commercial value would depend on hospital purchasing rules, anesthesia workflow, and whether the product qualifies for reimbursement or savings under operating-room efficiency programs.

High-concentration formulations

A higher-strength formulation could reduce injection volume, but it would require a careful assessment of viscosity, osmolality, pH, solution stability, injection force, and local tolerability. Sugammadex is already administered as a concentrated injectable solution, so the incremental benefit of increasing concentration may be modest unless a new presentation targets rapid emergency dosing.

High-concentration formulations can also create manufacturing and analytical burdens. Small changes in pH or ionic strength may affect solution behavior, impurity formation, and container compatibility.

Stable premixed bags

A premixed infusion bag is less commercially attractive than a syringe because sugammadex is generally administered as a bolus injection rather than a prolonged infusion. A bag could have value in limited institutional protocols, but it would increase container size, shipping cost, and microbiological control requirements without necessarily improving clinical workflow.

Lyophilized or dual-chamber products

Lyophilization could improve long-term stability in some injectable products, but it would add reconstitution steps that conflict with Bridion’s rapid operating-room use. A dual-chamber system would also add device cost and administration complexity. These formats are therefore weaker candidates unless solution stability, shipping conditions, or geographic distribution requirements create a clear benefit.

Excipient-free or minimal-excipient products

Bridion already has a minimal-excipient profile. A new product marketed as “clean label” would have limited differentiation unless it demonstrated a specific advantage, such as reduced container interaction, improved stability, or compatibility with a novel delivery device.

Which excipient suppliers have commercial opportunities?

The most credible opportunities are in supply and quality infrastructure rather than novel excipient chemistry.

Opportunity	Commercial rationale	Main barrier
Pharmaceutical-grade hydrochloric acid	Reliable pH adjustment supply	Low differentiation and multiple suppliers
Pharmaceutical-grade sodium hydroxide	pH control and manufacturing robustness	Commodity pricing
Water-for-injection systems	Critical process utility and supply continuity	Requires validated manufacturing infrastructure
Low-extractables vials	Supports injectable compatibility and shelf life	Regulatory and analytical qualification
Prefilled syringe components	Enables ready-to-administer product	Device compatibility and human factors
Elastomer closures	Reduces adsorption, leachables, and particulate risk	Supplier qualification and extractables testing
Secondary packaging	Light and handling protection	Lower margin, limited exclusivity
Contract fill-finish	Supports generic or licensed products	Sterile manufacturing capacity

Hydrochloric acid and sodium hydroxide are unlikely to support meaningful standalone exclusivity. Their value lies in pharmaceutical grade, batch consistency, low metals, low endotoxin burden, and documented change control. Water for injection can be commercially important because sterile injectable manufacturing depends on validated generation, storage, distribution, and monitoring systems.

What regulatory status applies to Bridion and its excipients?

The FDA approved Bridion in December 2015 for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery (U.S. Food and Drug Administration, 2015).

The product is a small-molecule injectable, not a biologic. Biosimilar pathways do not apply. Competing products would generally use the abbreviated new drug application pathway if they meet the relevant requirements for sameness, quality, strength, route, dosage form, and bioequivalence.

For excipients, the regulatory burden is driven by the route of administration and the proposed level of exposure. Even well-established injectable materials must meet applicable quality, sterility, endotoxin, particulate, and compatibility requirements. A novel excipient would face a materially higher regulatory burden than hydrochloric acid, sodium hydroxide, or water for injection.

What is the Orange Book and patent position for Bridion?

Bridion is listed in the FDA Orange Book as a prescription injectable drug. The Orange Book identifies patents and regulatory exclusivity relevant to abbreviated applications, but listing status, patent expiration, and pediatric exclusivity should be verified against the current FDA electronic Orange Book before making a launch or Paragraph IV decision (U.S. Food and Drug Administration, 2024a).

The most important point for excipient companies is that an excipient improvement does not automatically avoid an innovator patent. A generic or reformulated sugammadex product must evaluate:

• Drug substance and composition claims.
• Injectable formulation claims.
• Method-of-use claims covering reversal of neuromuscular blockade.
• Container or device claims.
• Manufacturing-process claims.
• Patent-listing status in the Orange Book.
• Potential Paragraph IV certification exposure.

A formulation containing the same active concentration and the same pH-adjusting system may face a different patent analysis from a product using a novel syringe, concentration, buffer system, or administration method. The commercial value of a new excipient strategy depends on whether the change creates enforceable claims and a regulatory pathway that supports the proposed differentiation.

When does Bridion lose exclusivity?

Bridion’s commercial exclusivity depends on separate patent, regulatory-exclusivity, and litigation factors. FDA approval in 2015 does not by itself establish the final generic-entry date. Patent expiration, pediatric exclusivity, patent-term adjustment, settlements, court decisions, and approval timing can alter actual entry.

Generic applicants may submit Paragraph IV certifications against listed patents. A patent challenge can trigger litigation and, in some circumstances, a 30-month stay of approval under the Hatch-Waxman framework. A settlement could permit an entry date earlier than patent expiration, subject to the agreement’s terms and antitrust scrutiny.

No biosimilar competition is relevant because sugammadex is a chemically defined small molecule. The principal competitive risk is generic sugammadex injection, followed by differentiated presentations such as prefilled syringes or institutional-use packaging.

What patent strategy could protect a sugammadex excipient product?

The strongest patent position would usually come from a defined technical improvement rather than the use of standard pH agents.

Potential claim categories include:

• A specific concentration range with improved stability.
• A defined pH window that reduces degradation.
• A container-closure combination that limits adsorption or leachables.
• A prefilled syringe with validated long-term compatibility.
• A ready-to-use presentation that maintains sterility and dose accuracy.
• A manufacturing process that reduces impurities or particulate formation.
• A formulation with improved low-temperature or accelerated stability.
• A specific packaging configuration that improves light protection or shipping robustness.

A patent directed only to replacing hydrochloric acid with another conventional acid would likely face a weaker inventive-step position unless the change produces an unexpected stability, compatibility, or manufacturing result.

How strong is Bridion’s excipient-related patent estate?

The excipient-related estate is likely narrower than the broader sugammadex composition and use estate because the marketed product uses a simple injectable vehicle and standard pH-adjustment materials. Commercial protection is more likely to arise from the active molecule, manufacturing processes, dosage regimen, and product-specific patents than from conventional excipient selection.

For a competitor, the key risk is not whether an excipient is itself patented. The key risk is whether the complete formulation, method of use, manufacturing process, or presentation falls within an unexpired claim.

For an investor or licensing team, the practical ranking is:

1. Container and device claims with a clear hospital-use benefit.
2. Stability claims supported by comparative data.
3. Manufacturing claims that improve yield or impurity control.
4. Novel injectable excipient systems.
5. Simple substitution of standard pH agents.

What litigation and settlement issues affect generic sugammadex?

Generic entrants should assess the full Orange Book patent set, FDA litigation records, and public court dockets. Relevant events include:

• Paragraph IV notices.
• Declaratory-judgment actions.
• Patent-infringement complaints.
• Preliminary injunction requests.
• ANDA settlements.
• Authorized-generic arrangements.
• Launch dates tied to patent settlements.

A settlement can change the practical market-entry date without eliminating technical or regulatory competition. An excipient supplier that licenses a formulation to a generic applicant should also review indemnification, supply commitments, change-control duties, and litigation-cooperation provisions.

What commercial opportunities exist outside the United States?

Geographic opportunity is strongest where operating-room demand is growing and injectable manufacturing capacity is constrained. Products may need country-specific packaging, labeling, stability data, and regulatory submissions.

Region	Excipient and formulation opportunity
United States	Generic injection, prefilled syringe, sterile fill-finish, hospital packaging
European Union	Generic authorization, centralized quality strategy, device-linked presentations
Japan	Local regulatory adaptation and high-quality injectable supply
China	Domestic manufacturing, local registration, hospital procurement
India	Cost-efficient generic production and export supply
Latin America	Room-temperature stability and robust secondary packaging
Middle East and Africa	Shipping stability, supply continuity, and simplified presentations

Export markets may place greater value on room-temperature stability, durable packaging, and reduced cold-chain dependence. Any claim of extended stability must be supported by product-specific data and accepted by the relevant regulator.

How does Bridion compare with competing reversal products?

Sugammadex competes primarily with neostigmine-based reversal strategies rather than with another cyclodextrin drug. Sugammadex offers direct encapsulation of rocuronium and vecuronium, while neostigmine acts through acetylcholinesterase inhibition and is commonly paired with an antimuscarinic agent.

Attribute	Sugammadex injection	Neostigmine-based reversal
Active mechanism	Encapsulation of steroidal neuromuscular blockers	Acetylcholinesterase inhibition
Typical excipient complexity	Low	Product-specific
Administration	Intravenous injection	Intravenous injection
Biosimilar risk	None	None
Generic risk	High once patents and exclusivity permit	Established generic competition
Formulation opportunity	Syringe, stability, container, concentration	Combination and presentation optimization
Hospital value driver	Rapid, predictable reversal	Lower acquisition cost

The low excipient complexity of sugammadex may support efficient generic manufacturing, but it also limits differentiation based solely on formulation ingredients.

What revenue exposure does Bridion create for Merck?

Bridion is a material commercial product for Merck’s hospital and perioperative portfolio. Merck reported approximately $1.3 billion in Bridion sales in 2023, making generic entry and price erosion relevant to revenue forecasting (Merck & Co., Inc., 2024).

The effect of generic competition would depend on:

• Number of approved generic suppliers.
• Timing of first generic entry.
• Whether an authorized generic is available.
• Hospital contracting behavior.
• Adoption of prefilled or device-enabled presentations.
• Geographic mix.
• Any litigation settlement controlling entry.

A differentiated excipient or container strategy could preserve pricing only if it produces measurable workflow, stability, safety, or supply advantages.

Key Takeaways

• Bridion uses a minimal injectable formulation: sugammadex sodium, water for injection, hydrochloric acid, and sodium hydroxide.
• Conventional excipient substitution offers limited commercial differentiation.
• The strongest opportunities are prefilled syringes, container-closure systems, sterile fill-finish, supply continuity, and stability improvements.
• Sugammadex is a small molecule, so biosimilar risk does not apply. Generic ANDA competition is the relevant threat.
• Any patent strategy should focus on validated formulation, device, packaging, stability, or manufacturing improvements.
• Current Orange Book listings, patent expirations, Paragraph IV filings, and settlements control the practical entry timetable.
• Bridion generated approximately $1.3 billion in Merck sales in 2023, creating meaningful exposure to generic price erosion.

FAQs About Bridion Excipients and Commercial Strategy

Does Bridion contain preservatives?

No. Bridion is supplied as a preservative-free, single-dose intravenous injection.

Can hydrochloric acid or sodium hydroxide create exclusivity for a sugammadex product?

Usually not by themselves. Standard pH-adjusting agents generally provide weak differentiation unless they produce a documented stability, compatibility, or manufacturing advantage.

Is sugammadex eligible for a biosimilar?

No. Sugammadex is a chemically synthesized small molecule. Competitors would generally pursue generic-drug pathways rather than biosimilar approval.

Could a prefilled Bridion syringe receive premium pricing?

Potentially. A premium would depend on demonstrated reductions in preparation time, dosing errors, product waste, or operating-room labor, together with regulatory approval and hospital purchasing acceptance.

What is the highest-value excipient opportunity for generic sugammadex?

The highest-value opportunity is likely an integrated product system combining pharmaceutical-grade injectable materials with a compatible prefilled syringe, validated container closure, and reliable sterile fill-finish supply.

References

1. Merck Sharp & Dohme LLC. (2023). Bridion (sugammadex) injection, prescribing information. U.S. Food and Drug Administration.

2. Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com

3. U.S. Food and Drug Administration. (2015). FDA approves Bridion to reverse effects of certain muscle relaxants used during surgery. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/